Inactivated *Mycobacterium phlei* inhalation ameliorates allergic asthma through modulating the balance of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T and Th<sub>17</sub> cells in mice

Moyu Ming<sup>1</sup>, Zhixi Luo<sup>1</sup>, Shengqiu Lv<sup>1</sup>, Qixiang Sun<sup>1</sup>, Chaoqian Li<sup>1*</sup>

<sup>1</sup>Department of Respiratory Medicine, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China 530021

**Abstract**

**Objective(s):** Th2 response is related to the aetiology of asthma, but the underlying mechanism is unclear. To address this point, the effect of nebulized inhalation of inactivated *Mycobacterium phlei* on modulation of asthmatic airway inflammation was investigated.

**Materials and Methods:** 24 male BALB/c mice were randomly divided into three groups: control group (Group A), asthma model group (Group B), and the medicated asthma model group (Group C). Group B and C were sensitized and challenged with ovalbumin (OVA). Group C was treated with aerosol *M. phlei* once daily before OVA challenge. Airway responsiveness in each group was assessed. All the animals were killed, and lung tissues and bronchoalveolar lavage fluid (BALF) were harvested. Inflammatory response, proportion of Th17 and CD4<sup>+</sup>CD25<sup>+</sup> Treg cells, and the levels of cytokines were analyzed in lung tissue.

**Results:** The proportion of Th17 cells and expression level of IL17, IL23, and IL23R were increased, while Foxp3 expression was decreased in Group B. Inhaling inactivated *M. phlei* inhibited airway inflammation and improved airway hyper-responsiveness, as well as peak expiratory flow (PEF). In addition, it significantly increased Th17 proportion, Foxp3 level, and the proportion of CD4<sup>+</sup>CD25<sup>+</sup> Treg cells in lung tissue in Group C.

**Conclusion:** Inactivated *M. phlei* was administered by atomization that suppressed airway inflammation and airway hyper-responsiveness partially via modulating the balance of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T and Th17 cells.

**Introduction**

Asthma is a chronic respiratory disease which is characterized by airway inflammation and hyper-reactivity. Although the pathogenesis of asthma remains to be determined, newly emerging CD<sub>4</sub><sup>+</sup>Th cell subsets have been linked to general disease pathogenesis, including regulatory T cells (Treg) (1), Th<sub>17</sub> cells (2), and the Th cells which produce IL10 (Th<sub>9</sub> cells) (3).

IL17 has been implicated in asthma development (4) and Th<sub>17</sub> cells are now accepted to represent a third CD<sub>4</sub><sup>+</sup>Th subset, which has led to the resolution of some inconsistencies in the Th<sub>1</sub>/Th<sub>2</sub> paradigm (5). Regulatory T cells are characterized by the expression of the transcription factor Foxp3 (Forkhead Foxp3) and the IL2 receptor (CD25), and are known to produce the inhibitory cytokines IL10 and TGF-β (6). The Treg cells have an ability to suppress allergic inflammation and asthma manifestations upon allergen provocation in mouse model of allergic asthma. The development of Treg cells can suppress airway inflammation via mediating the tolerance of respiratory mucosal surfaces to environmental allergens (7-9). The balanced action between Th<sub>17</sub> and Treg cells may be important for the development/prevention of inflammatory and autoimmune diseases such as asthma (10). Therefore, inducing both Th<sub>17</sub> and Treg cells using immunological tools might be a promising treatment for asthma, but technically it is difficult.

The global prevalence of asthma and allergic disease is continuously increasing, especially in population-dense countries in Africa, Latin America, and part of Asia (11, 12). In recent years, it was recognized that Th<sub>1</sub>/Th<sub>2</sub> imbalance does not fully explain the aetiopathogenesis of asthma, because reversing the Th<sub>1</sub>/Th<sub>2</sub> imbalance does not fully control asthmatic symptoms in human. Some studies have suggested that other CD<sub>4</sub><sup>+</sup> T cell subsets may play a role in asthma, including Th<sub>1</sub>, Th<sub>17</sub>, and regulatory T cells (Treg) (13). In terms of regulation and restriction of immune responses, researchers are particularly interested in exploring the roles of T regulatory cells and Th<sub>17</sub> cells. Extended
investigations have shown that *Mycobacterium bovis* bacille Calmette-Guérin (BCG) and other mycobacterial infections suppress airway hyperresponsiveness (AHR) and eosinophilic inflammation, likely through T-helper 1 (Th1) or regulatory T cell (Treg) responses (14–19).

Our previous study showed the inhalation of *Mycobacterium phlei* reduces airway inflammation in asthmatic mice via altering the balance of the Th1/Th2 responses (20). This study aimed to determine whether *M. phlei* administered by atomization, affect CD4/CD25+ regulatory T cells/Th17 balance in a mouse model of asthma.

### Materials and Methods

#### Animals

Male BALB/c mice (6 weeks old, pathogen free) were obtained from Laboratory Animal Center of Guangxi Medical University. All experiments were approved by the Animal Care Committee at Guangxi Medical University (Nanning, Guangxi, China). 24 male BALB/c mice were randomly divided into 3 experimental groups: the control group (Group A), the asthma model group (Group B), and the prevention group (Group C). All mice were maintained in an air-conditioned room at 23±3 °C and 55.5±10% humidity, and fed a standard laboratory diet with *ad libitum* access to food and water.

#### Sensitization and airway challenge

BALB/c mice were sensitized and challenged with ovalbumin (OVA) to establish a murine model of asthma (10). In brief, Group B and Group C were sensitized by IP injection of 25 mg OVA (grade V; Sigma) emulsified in 1 mg of aluminum hydroxide (AlumImject; Pierce, Rockford, IL) in a total volume of 200 μl, on day 1 and 14. Mice were challenged (20 min) via the airways with OVA (2% in saline) for 7 days (from day 21 to day 28) using ultrasonic nebulization (AeroSonic ultrasonic nebulizer; DeVilbiss, Somerset, PA). Group A received only saline (instead of OVA).

#### Mycobacterial preparations, prevention protocols

Inactivated *M. phlei* (1.72 μg) was dissolved in 10 ml saline and injected (20). Group C as treated with inactivated *M. phlei*, once daily before each OVA challenge using ultrasonic nebulization, as described (20). Group A and B were treated with the same dose of saline. Twenty-four hr after the last challenge, AHR was assessed, and the lung tissues were collected for further analysis.

#### Airway hyper responsiveness assessment

Respiratory resistance (RL, cmH2O.s/ml) was assessed in anesthetized and tracheotomized mice that were mechanically ventilated in response to increasing dose of methacholine inhalation, using the pulmonary function equipment from RC System for Mouse [Buxco Research Systems 2033 Corporate Drive Wilmington, NC 28405 USA] (21).

#### Histological examination of murine lung tissue

For histopathological analysis, lung tissue was fixed with 10% formalin for 24 hr, after bronchoalveolar lavage fluid (BALF) collection. Lung samples were embedded in the paraffin. Microtome sections were cut in a 5 μm thickness and stained with haematoxylin and eosin (H&E) for analyzing airway inflammation and pathological changes (22).

#### Immunohistochemical analysis

For immunohistochemical detection of IL17 and IL23R in lung, the tissue sections were incubated overnight at 4 °C with the primary antibodies directed against IL17 (Santa Cruz biotechnology, Inc, USA) and IL23R (R&D Systems, Inc. Minneapolis, MN, USA). Image analysis was performed using a microscope (Leica, Germany). For BALF analysis, mice were anesthetized with chloral hydrate (10%, 0.04 ml/10 g body weight). The trachea was cannulated, and BALF was collected after injections of 0.5 ml saline dissolved in the phosphate buffer, into the lung. The BALF was centrifuged, and the supernatant was used to test the cytokine production. The experiments were followed a protocol as described (23).

#### Cytokine enzyme-linked immunosorbent assay

The serum concentration of IL17 and IL23 (R&D Systems, Inc) in the supernatants of the cultured cells as measured by enzyme-linked immunosorbent assay (ELISA) using the ELISA kit (Thermo Fisher Scientific) based on the instructions of the manufacturer.

#### RNA extraction and RT-PCR

Total RNA from lung tissues was extracted with Trizol reagent (Invitrogen, Gaithersburg, USA) according to the manufacturer's instructions. Complementary DNA (cDNA) was generated using a cDNA reverse transcription kit (Invitrogen, Gaithersburg, USA) according to the manufacturer’s instructions. Real-time polymerase chain reaction (RT-PCR) was performed by adding SYBR green I (Roche Diagnostics, Mannheim, Germany), and mouse IL17, Foxp3, and β-actin were amplified. Primer sequences were used as follow; IL17 (F: GCCAAGCTGGACCCACAGCA and R: CACACCACCCAGCATCTTTC), Foxp3 (F: TACACTGTGTCCACACCGCATG and R: CACCCGCCAAAAGACTCT), and β-actin (F: ATCCACGAAACTCCTTCAC and R: CACCCGCACCGAGCACCAG). LightCycler™ (Roche Diagnostics). The relative expression levels were calculated by normalizing the IL17 and Foxp3 levels to that of β-actin mRNA.
Detection of Th17 and CD4+CD25+ Treg cells by flowcytometry

Lung tissues were removed and placed in PBS solution. Tissues were dispersed into single-cell suspensions. Peripheral blood mononuclear cells (PBMCs) were isolated by a density gradient centrifugation on Ficoll-Hypaque (24).

For cell-surface staining, CD4+ (clone GK1.5), CD25+ (clone eBio3C7), and Foxp3 (clone FJK-16S) antibodies were obtained from eBioSciences. For measurement of intracellular cytokines, T cells were stimulated with 500 ng/ml Phorbol dibutyrate (PdBu) and 500 ng/ml ionomycin in the presence of 1 mg/ml Brefeldin A (Sigma), for 2 hr. Cells were then fixed with 3.65% formaldehyde solution (Sigma) and permeabilized in a 0.1% NP40 containing buffer before analysis. IL-17A (clone TC11) antibody was obtained from eBioSciences. Intracellular staining and cell-surface staining were performed according to the manufacturer's instructions.

Measurement of PFP after methacoline stimulation

25 cross-section samples randomly selected from each group at complete peer trachea were used to analyze the score of airway wall inflammatory cell infiltration, as described below (25). The scoring is as follows: 0: no inflammatory cell infiltration; 1: a small amount, intermittent inflammatory cells; 2: airway wall surrounded with a thin layer of inflammatory cells (1-5 cells thin); 3: airway wall surrounded with thick layer of inflammatory cells (more than 5 cell layers).

Statistical analysis

The experimental values were presented as mean± standard deviation. Statistical analysis was performed with the statistical software package SigmaStat (SPSS 17.0, Chicago, IL). Significant differences in expression of IL-17, IL-23R, and Foxp3 in different groups were analyzed by using the Kruskal–Wallis test. All assays were compared using ANOVA followed by least squares difference analysis. Differences were considered statistically significant when the P-value<0.05.

Results

Inactivated M. phlei administration suppressed airway inflammation

Our previous study identified that the inhalation of M. phlei reduces airway inflammation in asthmatic mice via altering the balance of the Th1/Th2 responses (20). To further monitor the effects of inactivated M. phlei on pathological changes in lung tissues, H&E was used to stain the lung tissues from the normal mice (Group A), asthmatic mice (Group B), and inactivated M. phlei inhaling asthmatic mice (Group C). In Group A, bronchial wall was smooth and complete without inflammatory cells surround the lung tissue, airway, and blood vessels. In OVA-immunized mice (Group B), OVA challenge induced infiltration of inflammatory cells. Inactivated M. phlei administered by inhalation led to a significant suppression of inflammatory cells recruitment into the airways. To explore pathological differences in
Table 1. PEF (ml/s) in three group (x̄±s, n= 8)

| Methacholine (mg/mL) | 0 | 6.25 | 12.5 | 25 | 50 |
|----------------------|---|------|------|----|----|
| Group A              | 1.46±0.02 | 1.06±0.09 | 0.75±0.10 | 0.49±0.14 | 0.39±0.16 |
| Group B              | 1.04±0.11 | 0.93±0.06 | 0.48±0.13 | 0.45±0.13 | 0.31±0.08 |
| Group C              | 1.42±0.03 | 1.12±0.08 | 0.93±0.17 | 0.65±0.16 | 0.47±0.12 |
| F                  | 54.925 | 7.901 | 12.393 | 2.659 | 2.000 |
| P                  | 0.000 | 0.006 | 0.001 | 0.111 | 0.178 |

Figure 2. Airways resistance to increasing concentrations of methacholine. Inhalation of inactivated M. phlei suppressed asthmatic airway hyper-responsiveness (AHR). Compared with Group A, *P<0.01. Compared with Group C, #P<0.01. Group A: normal control group; Group B: asthma model group; Group C: the prevention group.

Three groups, abnormal wall of airway was counted from each group. The results showed that OVA challenge significantly increased percentage of abnormality (96%) than normal group (8%), and inactivated M. phlei treatment slightly rescued it (76%). In addition, histochemical analyses revealed that inactivated M. phlei administration suppressed IL17 and IL23R expressions, and increased Foxp3 level, which were similar with normal mice (Figure 1).

Inactivated Mycobacterium phlei administration reduced airway hyper responsiveness

Airway hyper responsiveness was analyzed in three groups (Figure 1). After OVA immunization, airway hyper responsive was significantly increased, while peak expiratory flow (PEF) was decreased in Group B compared to normal mice (P<0.01).

However, inactivated M. phlei treatment inhibited the increase of airway sensitivity, as well as increased PEF in OVA immunization asthmatic mice model in Group C (P<0.05) (Figure 2). Similar with OVA challenge, Methacholine-mediated PEF levels were also lower in Group B, but inactivated M. phlei treatment rescued this decrease (Table 1).

Cytokines (IL17 and IL23) levels in BALF, and IL17 and Foxp3 transcript levels in lung were changed by inactivated M. phlei treatment

To further characterize the effects of inactivated M. phlei inhalation, the concentration of IL17 and IL23 in BALF was measured by ELISA, and the mRNA level of IL17 and Foxp3 was assessed by RT-PCR. As shown...
In Figure 3, the concentration of IL-17 and IL-23 in BALF and the level of IL-17 mRNA were increased in Group B, but they were decreased by the treatment of inactivated M. phlei in Group C. However, there was no significant change in the Foxp3 mRNA level between the three groups.

**Inactivated M. phlei administration increased percentage of Th17 and CD4+CD25+ Treg cells in lung**

Inhalation of *M. phlei* was known to change the balance of the Th1/Th2 responses (20). To further address its effects on other type of cells in lung, Th17 and CD4+CD25+ Treg cells were monitored in normal mice (Group A), asthmatic mice (Group B), and inhaled inactivated *M. phlei* asthmatic mice model (Group C). As shown in Figure 4, the percentage of Th17 cells was significantly high and CD4+CD25+ Treg cells were obviously low in Group B. However, the percentage of Th17 cells was significantly low and CD4+CD25+ Treg cells were obviously high in Group C. The percentage of T cell and Th17 cells in lung was also analyzed. Data showed that T/Th17 cell ratio was decreased in Group B compared to Group A, and it was partially recovered in Group C (Figure 5).

**Discussion**

Nonspecific immunosuppressive therapy is one of the current treatments of asthma. Immunization with *mycobacteria* or *mycobacteria* products has been reported to inhibit the development of allergic disease (16, 17, 26, 27). The most acceptable approach is the exposure to a range of mainly innocuous microorganisms, largely bacteria to trigger protective responses in the developing immune system. These effects are probably activated through innate immune receptors such as TLR2 (28), and might affect the development of responses mediated by several cell types including basophils, natural killer cells (29), dendritic cells (30), and T-regulatory (Treg) cells (31).

Extensive studies have reported that *mycobacteria* such as BCG have suppressive effects on asthma (14-16, 18, 32-36). Many factors affect the induction of immune responses by *mycobacteria*, such as *mycobacteria* strains (37) and route of administration. Oral exposure to bacterial extracts, protects animals against the development of experimental models of asthma (30, 31). The present study demonstrated that inhalation of inactivated *M. phlei* is a way to treat asthma. OVA challenge (Group B) increased the levels of IL-17 and IL-23R, the concentration of IL-17 and IL-23, and the proportion of Th17 cells, while reduced the level of Foxp3. Our results also showed that inhalation of inactivated *M. phlei* suppressed the airway inflammation and hyperreactivity, reduced the production of IL-17 and IL-23, the proportion of Th17, and the expression of IL-23R in asthmatic mice. Inhaling inactivated *M. phlei* promoted the expression of Foxp3 and the proportion of CD4+CD25+ Treg cells in Group C.

Previous studies reported the effects of *Mycobacterium* on Th17 and/or Treg cells (38-41). In which, lower expression of Th17-associated cytokines...
and higher expression of CD4+CD25+Treg cells were observed in the treated mice than the untreated asthmatic mice model, which is similar with our findings in current study. However, conflicting results exist when it comes to which T cells produce IL_{17} and are affected by BCG in asthma. Deng and colleagues (42) showed that BCG neonatal vaccination reduced IL_{17} production in both the BALF and the lung lymphocytes, in asthmatic mice. They also showed that BCG neonatal vaccination did not reduce Th_{17} cells. Although effective, immunotherapy by injection of BCG has the potential for systemic side effects including sclerosis, ulcer, fever, and even tuberculosis diffusion. The inhalation of certain drugs was suggested as early as 1946 (43), and now is commonly used for the patients with asthma and chronic obstructive pulmonary disease (44). Inhalation delivery of the drugs to lungs offers several substantial advantages such as simplified administration protocol, reduced drug quantity needed to achieve therapeutic effect, and increased drug concentration at the required sites (45) and is suitable to be used for children especially. Moreover, the initial interactions of microbes with epithelial cells, dendritic cells, and macrophages at the mucosal surface create potential to activate a wide range of different lymphoid types (46). In our study, inhalation of inactivated M. phlei successfully reduced airway inflammatory response and balanced proportion of Th_{17} and CD4+CD25+Treg cells, as well as the levels of cytokines in lung tissue after being immunized by OVA. Based on our findings, inhalation of inactivated M. phlei is an efficient approach to treat asthma.

**Conclusion**

The present study demonstrated that inhaled inactivated M. phlei is able to ameliorate allergic asthma via modulating the balance between CD4+CD25+regulatory T cells and Th_{17} cells in mice. Therefore, our data underlines the importance of inhaling inactivated M. phlei as a potential approach for the therapeutic modulation of asthma.

**Acknowledgment**

This work was made possible by a grant (81360007) from National Natural Science Foundation of China.

**References**

1. Robinson DS. Regulatory T cells and asthma. Clin Exp Allergy 2009; 39:1314-1323.
2. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. The J Allergy Clin Immunol 2009; 123:1004-10011.
3. Sorooosh P, Doherty TA. Th9 and allergic disease. Immunology 2009; 127:450-458.
4. Hellings PW, Kasran A, Liu Z, Vandekerckhove P, Wufts A, Overbergh L, et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am J Respir Cell Mol Biol 2003; 28:42-50.
5. Durrant DM, Metzger DW. Emerging roles of T helper subsets in the pathogenesis of asthma. Immunol Invest 2010; 39:526-249.
6. Wing K, Fehervari Z, Sakauchi S. Emerging possibilities in the development and function of regulatory T cells. Int Immunol 2006; 18:991-1000.
7. Ryanna K, Stratigou V, Safinia N, Hawrylowicz C. Regulatory T cells in bronchial asthma. Allergy 2009; 64:335-347.
8. Akdis CA, Akdis M. Mechanisms and treatment of allergic disease in the big picture of regulatory T cells. J Allergy Clin Immunol 2009; 123:735-746; quiz 47-48.
9. Palomares O, Yamant G, Azkur AK, Akkoc T, Akdis M, Akdis CA. Role of Treg in immune regulation of allergic diseases. Eur J Immunol 2010; 40:1232-1240.
10. Sakauchi S, Ono M, Setoguchi R, Yagi H, Hori S, Fehervari Z, et al. Foxp3+ CD25+ CD4+ natural regulatory T cells in dominant self-tolerance and autoimmune disease. Immunol Rev 2006; 212:8-27.
11. Annesi-Maesano I, Mourad C, Daures JP, Kalaboka S, Godard P. Time trends in prevalence and severity of childhood asthma and allergies from 1995 to 2002 in France. Allergy 2009; 64:798-800.
12. Asher MI. Recent perspectives on global epidemiology of asthma in childhood. Allergol Immunopathol 2010; 38:83-87.
13. Afshar R, Medoff BD, Luster AD. Allergic asthma: a tale of many T cells. Clin Expe Allergy 2008; 38:1847-1857.
14. Koh YI, Choi IS, Kim WY. BCG infection in allergen-persensitized rats suppresses Th2 immune response and prevents the development of allergic asthmatic reaction. J Clin Immunol 2001; 21:51-59.
15. Erb KJ, Holloway JW, Sobeck A, Moll H, Le Gros G. Infection of mice with Mycobacterium bovis-Bacillus Calmette-Guerin (BCG) suppresses allergen-induced airway eosinophilia. J Exp Med 1998; 187:561-569.
16. Herz U, Gerhold K, Gruber C, Braun A, Wahn U, Renz H, et al. BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model. J Allergy Clin Immunol 1998; 102:867-874.
17. Wang CC, Rook GA. Inhibition of an established allergic response to ovalbumin in BALB/c mice by killed Mycobacterium vaccae. Immunology 1998; 93:307-313.
18. Hopfenspirger MT, Agrawal DK. Airway hyper responsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J Immunol 2002; 168:2516-2522.
19. Zuany-Amorim C, Sawicka E, Manlius C, Le Moine A, Brunet LR, Kemeny DM, et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med 2002; 8:625-629.
20. Zhang J, Li C, Guo S. Effects of inhaled inactivated Mycobacterium phlei on airway inflammation in
mouse asthmatic models. 1 Aerosol Med Pulm Drug Deliv 2012; 25:9-6-103.
21. Cheng C, Ho WE, Goh FY, Guan SP, Kong LR, Lai WQ, et al. Anti-malarial drug artesunate attenuates experimental allergic asthma via inhibition of the phosphoinositide 3-kinase/Akt pathway. PloS One 2011; 6:e20932.
22. Qu SY, Ou-Yang HF, He YL, Wan Q, Shi J R, Wu CG. Der p 2 recombinant bacille Calmette-Guerin targets dendritic cells to inhibit allergic airway inflammation in a mouse model of asthma. Respiration 2013; 85:49-58.
23. Karani L, Tolo F, Karanja S, Khayeka C. Safety and efficacy of Prunus africana and Warburgia ugandensis against induced asthma in BALB/c Mice. Eur J Med Pl 2013; 3:345-368.
24. Tsai YG, Niou DM, Yang KD, Hung CH, Yeh YJ, Lee CY, et al. Functional defects of CD46-induced regulatory T cells to suppress airway inflammation in mite allergic asthma. Lab Invest 2012; 92:1260-1269.
25. Roh GS, Seo S-W, Yeo S, Lee JM, Choi J-W, Kim E, et al. Efficacy of a traditional Korean medicine, Chung-Sang-Bo-Ha-Tang, in a murine model of chronic asthma. Int Immunopharmacol 2005; 5:427-436.
26. Yang X, Wang S, Fan Y, Zhu L. Systemic mycobacterial infection inhibits antigen-specific immunoglobulin E production, bronchial mucus production and eosinophilic inflammation induced by allergen. Immunology 1999; 98:329-337.
27. Cavallo GP, Elia M, Giordano D, Baldi C, Cammarota R. Decrease of specific and total IgE levels in allergic patients after BCG vaccination: preliminary report. Arch Otolaryngol Head Neck Surg 2002; 128:1059-1060.
28. Round JL, Lee SM, Li J, Tran G, Jabri B, Chatila TA, et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 2011; 332:974-977.
29. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336:489-493.
30. Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleury S, Lazzari A, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol 2011; 4:53-65.
31. Strickland DH, Judd S, Thomas JA, Larcombe AN, Sly PD, Holt PG. Boosting airway T-regulatory cells by gastrointestinal stimulation as a strategy for asthma control. Mucosal Immunol 2011; 4:43-52.
32. Han ER, Choi IS, Eom SH, Kim HJ. Preventive effects of mycobacteria and their culture supernatants against asthma development in BALB/c mice. Allergy Asthma Immunol Res 2010; 2:34-40.
33. Choi IS, Lin XH, Koh YA, Koh YI, Lee HC. Strain-dependent suppressive effects of BCG vaccination on asthmatic reactions in BALB/c mice. Ann Allergy Asthma Immunol 2005; 95:571-578.
34. Choi IS, Lin XH, Koh YA, Cui Y. Induction route-dependent and allergen-specific suppressive effects of bacille Calmette-Guerin vaccination on asthmatic reactions in BALB/c mice. Lung 2007; 185:179-186.
35. Lagranderie M, Vanoirbeek JA, Vargaftig BB, Guyonvarc'h P-M, Marshal G, Roux X. Therapeutic administration of Mycobacterium bovis BCG killed by Extended Freeze-Drying modulates airway inflammation in a chronic murine model of asthma. Open J Respir Dis 2013; 3:79.
36. Deng Y, Li W, Luo Y, Wang LJ, Xie XH, Luo J, et al. Inhibition of IFN-y promotes anti-asthma effect of Mycobacterium bovis Bacillus Calmette-Guerin neonatal vaccination: A murine asthma model. Vaccine 2014; 32:2070-2078.
37. Arnoldussen DL, Linehan M, Sheikh A. BCG vaccination and allergy: a systematic review and meta-analysis. J Allergy Clin Immunol 2011; 127:246-253, S3.e1-21.
38. Qu SY, Ou-Yang HF, He YL, Li ZK, Shi J R, Song LQ, et al. Der p2 recombinant bacille Calmette-Guerin priming of bone marrow-derived dendritic cells suppresses Der p2-induced T helper17 function in a mouse model of asthma. Respirology 2014; 19:122-131.
39. Ahrens B, Gruber C, Rha RD, Freund T, Quarcoo D, Awagyan A, et al. BCG priming of dendritic cells enhances T regulatory and Th1 function and suppresses allergen-induced Th2 function in vitro and in vivo. Int Arch Allergy Immunol 2009; 150:210-220.
40. Yao B, Li M, Pang Y. [Effect of Mycobacterium phelei FJU.36 on balance of CD4(+)CD25(+) regulatory T cells and Th17 cells in asthmatic mice]. Zhongguo Dang Dai Er Ke Za Zhi = Chinese J Contemporary Pediatr 2013; 15:1018-1022.
41. Xia Y, Zhang JH, Ji ZH, Li XD, Yu ZW, Liu HY. [Effect of bacillus calmette-guerin treatment on airway inflammation and T regulatory cells in mice with asthma]. Zhongguo Dang Dai Er Ke Za Zhi = Chinese J Contemporary Pediatr 2006; 8:413-416.
42. Deng Y, Chen W, Zang N, Li S, Luo Y, Ni K, et al. The antiasthma effect of neonatal BCG vaccination does not depend on the Th17/Th1 but IL-17/IFN-gamma balance in a BALB/c mouse asthma model. J Clin Immunol 2011; 31:419-429.
43. O’Callaghan C, Barry PW. The science of nebulised drug delivery. Thorax 1997; 52:S31-44.
44. Melani AS. Inhalatory therapy training: a priority challenge for the physician. Acta Biomed 2007; 78:233-245.
45. Torchilin VP. Drug targeting. Eur J Pharm Sci 2000; 1:881-91.
46. Hansel TT, Johnston SL, Openshaw PJ. Microbes and mucosal immune responses in asthma. Lancet 2013; 381:861-873.